Second chance: vyxeos targets tough leukemia after standard chemo fails
NCT ID NCT04049539
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a drug called Vyxeos in adults with acute myeloid leukemia (AML) whose cancer did not go away after standard chemotherapy. Vyxeos combines two chemo drugs inside a tiny fat bubble (liposome) to deliver them more effectively. The trial will check for side effects and see how many patients achieve remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vyxeos (a liposome containing two chemotherapy drugs: cytarabine and daunorubicin)
What this could lead to
If it works, this could offer a treatment option for people with acute myeloid leukemia who did not get better after standard chemotherapy.
What could go wrong
This is a small, early-phase trial (Phase 1/2) with only 28 participants. The drug may not work for everyone, and side effects like infections, heart problems, or bleeding are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
UC Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact